![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1351550
¼Òº¯ °Ë»ç ½ÃÀå ±Ô¸ð - Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ¼¼°è ¿¹Ãø(2023-2032³â)Urinalysis Market Size - By Product (Consumables, Instruments), By Application (Urinary Tract Infections [UTI], Kidney Disease, Pregnancy, Diabetes), By End-Use (Clinical Laboratories, Hospitals, Home Healthcare), Global Forecast 2023 - 2032 |
¼¼°è ¼Òº¯ °Ë»ç ½ÃÀåÀº 2023³âºÎÅÍ 2032³â±îÁö CAGR 5.2%¸¦ ±â·ÏÇÒ °ÍÀÔ´Ï´Ù.
ÀÌ·¯ÇÑ ¹è°æ¿¡´Â ¿ä·Î °¨¿°°ú ½ÅÀå ÁúȯÀÇ Áõ°¡°¡ ÀÖ½À´Ï´Ù.
CDC¿¡ µû¸£¸é, ¹Ì±¹¿¡´Â ¾à 3,550¸¸ ¸íÀÇ ¼ºÀÎÀÌ ¸¸¼º ½ÅÀå ÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ´Â Áø´Ü µµ±¸·Î¼ ¼Òº¯ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °í·ÉȰ¡ ÁøÇàµÇ¸é¼ ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, Á¤±âÀûÀÎ ¼Òº¯ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù. °Ç° °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Àû±ØÀûÀÎ ¿¹¹æÀû ÀÇ·á ´ëÃ¥ÀÌ Á¤±âÀûÀÎ ¼Òº¯ °Ë»çÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °³¹ßµµ»ó±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®Ãæ°ú Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå È®´ë°¡ ´õ¿í °¡¼Ó鵃 °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¼Òº¯ °Ë»ç´Â Çö´ë ÀÇ·áÀÇ Çʼö ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.
Àüü ¼Òº¯ °Ë»ç ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.
Á¦Ç°º°·Î´Â ±â±â ºÎ¹®ÀÌ 2023³âºÎÅÍ 2032³â±îÁö 6.4%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿ä·Î °¨¿° ¹× ¸¸¼º ½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Áúº´ Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼Òº¯ °Ë»ç Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÈÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
´ç´¢º´ ÀÀ¿ë ºÐ¾ßÀÇ ¼Òº¯ °Ë»ç »ê¾÷Àº 2023³âºÎÅÍ 2032³â±îÁö 9.3%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´ÀÇ È®»êÀº ÇâÈÄ ¸î ³â µ¿¾È ÀÌ ºÎ¹® ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ´ç´¢º´ ȯÀÚÀÇ Áõ°¡´Â ¿ä´ç ¹× ÄÉÅæÃ¼ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ´ç´¢º´ °ü¸® ¹× ¸ð´ÏÅ͸µ¿¡¼ ¼Òº¯ °Ë»çÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù.
ÃÖÁ¾ ¿ëµµº°·Î º¸¸é ÀÓ»ó ½ÇÇè½Ç ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 5.9%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤±â °Ç° °ËÁø¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Áúº´ À¯º´·ü Áõ°¡, Áø´Ü ±â¼ú ¹ßÀü, ¿¹¹æÀû °Ç° °ü¸® Ãß¼¼ Áõ°¡´Â ÀÓ»ó ½ÇÇè½Ç¿¡¼ ¼Òº¯ °Ë»ç ÀýÂ÷ÀÇ Ã¤ÅÃÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
Áö¿ªº°·Î º¸¸é ¶óƾ¾Æ¸Þ¸®Ä«(LATAM)ÀÇ ¼Òº¯ °Ë»ç »ê¾÷Àº 2023³âºÎÅÍ 2032³â±îÁö CAGR 4.3%·Î ¼ºÀåÇÒ °ÍÀÔ´Ï´Ù. ¼ºÀåÀÇ ¹è°æ¿¡´Â ÀÇ·á ÁöÃâ Áõ°¡¿Í ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë°¡ ÀÖ½À´Ï´Ù. °í·ÉÈ Àα¸ÀÇ Áõ°¡, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¸¸¼º Áúȯ ¹ßº´·ü Áõ°¡µµ ÀÌ Áö¿ªÀÇ ¼Òº¯ °Ë»ç ¹× ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
Global urinalysis market will reflect 5.2% CAGR over 2023-2032. This is attributed to the increasing prevalence of urinary tract infections and kidney diseases.
According to the CDC, nearly 35.5 million adults in the U.S. suffer from chronic kidney disease. This is propelling the demand for urinalysis tests as a diagnostic tool which will propel market growth. The aging global population is also contributing to a higher incidence of chronic diseases, necessitating regular urine monitoring. Rising healthcare awareness and proactive preventive healthcare measures are further boosting the adoption of routine urine testing. Expanding healthcare infrastructure in developing regions and the growing emphasis on early disease detection may further drive market expansion, making urinalysis a vital component of modern healthcare.
The overall urinalysis market is categorized based on product, application, end-use and region.
Based on product, the instrument segment will exhibit a 6.4% CAGR from 2023 to 2032. Growing awareness about the importance of early disease detection alongside the increasing prevalence of urinary tract infections and chronic kidney diseases will fuel demand for urinalysis instruments, accelerating segment growth.
Urinalysis industry from the diabetes application segment is expected to witness a 9.3% CAGR from 2023 to 2032. The escalating global diabetes epidemic will drive the segment growth in the forthcoming years. Increasing diabetic patient populations are boosting the demand for urine glucose and ketone testing, emphasizing the vital role of urinalysis in diabetes management and monitoring.
By end-use, clinical laboratories segment is expected to grow at a 5.9% CAGR throughout the forecast period. The increasing demand for routine health check-ups, rising disease prevalence, advancements in diagnostic technology, and the growing trend towards preventive healthcare will drive the adoption of urinalysis procedures in clinical laboratories.
Regionally, the Latin American (LATAM) urinalysis industry will grow at a 4.3% CAGR from 2023 to 2032. The growth is attributed to rising healthcare expenditure and expanding access to healthcare services. An increase in the aging population, growing awareness of preventive healthcare, and the rising incidence of chronic diseases are also boosting demand for urinalysis tests and services in the region.